Answers are grounded in this paper and cite their sources.
Enhanced gastric residence time is exhibited by floating dosage forms. In vitro studies and animal model of retention potential is different due to their development. The main content of this research about the determination of the intragastric behaviour of acetohydroxamic acid floating microballoons in rabbit stomach by x-ray study and estimate the bioavailability of this drug in rabbit plasma by calculating pharmacokinetic parameters and comparision of these results with marketed formulation. Based on the evaluation of floating and dissolution behavior, formulation (AHF5) which showed complete release within 12 h and superior entrapment efficiency can be optimized by the formulation which proceeded as in vivo studies. From the radiographic images, it is showed the formulation was there buoyant at the stomach upto 6 h which indicates the formulation distribution. At unfed condition, the formulation is still buoyant at 3 h in the stomach due to fasting condition, the migrating myoelectric contraction by the pressure of contents in stomach by duodenum. In healthy albino rabbits, the in vivo pharmacokinetic studies were performed. The parameters of pharmacokinetic studies of the floating acetohydroxamic acid microballoons are differentiate with Lithostat tablets. The result are showed that AHF5 bioavailability has increased when correlate with marketed formulation. Relative bioavailability has found to be 124.9 with respect to formulation in market was found to be 124.9 because of prolonged residence time in gastric of floating acetohydroxamic acid microballoons.
No takes yet. Share an insight, caveat, or question.
Pancheddula et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: